Elo Mutual Pension Insurance Co Grows Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Elo Mutual Pension Insurance Co boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 10.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,581 shares of the life sciences company’s stock after purchasing an additional 1,431 shares during the quarter. Elo Mutual Pension Insurance Co’s holdings in Illumina were worth $2,082,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. WCM Investment Management LLC increased its stake in shares of Illumina by 26.6% during the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock worth $551,625,000 after buying an additional 867,673 shares during the period. ARK Investment Management LLC purchased a new stake in shares of Illumina in the 4th quarter valued at approximately $91,714,000. Janus Henderson Group PLC raised its holdings in shares of Illumina by 40.5% in the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after purchasing an additional 625,245 shares in the last quarter. Nikko Asset Management Americas Inc. purchased a new stake in shares of Illumina during the 4th quarter worth $65,813,000. Finally, Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Illumina by 116.9% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 865,546 shares of the life sciences company’s stock worth $115,663,000 after purchasing an additional 466,519 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on ILMN shares. Barclays reaffirmed an “underweight” rating on shares of Illumina in a report on Tuesday, March 11th. Stephens reaffirmed an “overweight” rating and issued a $156.00 price target on shares of Illumina in a report on Tuesday, March 11th. Piper Sandler raised their price objective on shares of Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Robert W. Baird lowered their target price on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th. Finally, HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target on the stock. in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $140.90.

Illumina Stock Down 2.8 %

ILMN stock opened at $80.00 on Friday. The stock has a market capitalization of $12.67 billion, a PE ratio of -10.42, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The company has a fifty day moving average of $102.80 and a 200-day moving average of $126.81. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina, Inc. has a one year low of $79.30 and a one year high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.